The proposed revision to R01HD074346 is designed to extend the project to a new disorder: autism spectrum disorder (ASD). Promising new pharmacological and behavioral treatments are being developed for numerous intellectual and developmental disabilities (IDD), including ASD. Evaluation of these treatments, however, is hampered by a lack of adequate outcome measures. Beginning 03-01-2013, our team was funded to evaluate the adequacy of expressive language sampling (ELS) for deriving outcome measures. In ELS procedures, samples of spoken language are collected in highly structured, yet naturalistic, interactions. The samples are analyzed to derive outcome measures reflecting important dimensions of language skill and atypical language behavior. ELS procedures yield clinically relevant and functional endpoints, capture language impairments common to IDD as well as impairments specific to particular IDDs, and yield robust indicators of developmental change within typical and language-impaired populations. In the already funded project, we are focused on children, adolescents, and young adults with fragile X syndrome (FXS) and Down syndrome (DS). In terms of specific aims, we are (1) examining the basic psychometric properties of measures derived from ELS procedures, including test-retest reliability, internal consistency, validity, and sensitivity; (2) evaluating differences in the psychometric properties o ELS procedures as a function of variations in participant etiology, age, gender, autism symptom severity, and IQ; (3) comparing the psychometric properties of three different ELS contexts (conversation, narration, and the Autism Diagnostic Observation Schedule-2); and (4) evaluating the feasibility of implementing ELS procedures across multiple sites. Test-retest reliability is being assessed at 4 weeks (+/- 1 week) using alternate versions of ELS materials. Internal consistency is being assessed by computing alpha coefficients within and across sampling contexts. Norm-referenced standardized tests and informant report are the indicators of construct validity. Longitudinal follow-up will yield an estimate of sensitivity to change relatve to existing measures. In this revision, we propose to add participants with ASD, which is a population that overlaps with FXS and DS (e.g., many individuals with ASD have a comorbid intellectual disability). At the same time, however, ASD is associated with a wider range of language and cognitive abilities than is FXS or DS, which has made the task of identifying valid outcome measures more challenging. ASD participants will be tested at two new sites (University of Minnesota and University of Washington), as well as at UC Davis. The data collected will be relevant to all four specific aims of the already funded project, but offers a fuler evaluation of the generalizability of ELS procedures and adds ASD, a highly prevalent IDD condition in desperate need of new tools for evaluating treatment efficacy.

Public Health Relevance

The increasing prevalence of ASD has led to an intense interest in the development of new pharmaceutical and behavioral treatment. Evaluation of the efficacy of these treatments, however, is hampered by the lack of adequate outcome measures. In this revision, we propose to evaluate the adequacy of expressive language sampling (ELS) procedures for deriving language-relevant outcome measures for individuals with ASD.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
3R01HD074346-03S1
Application #
9014358
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
King, Tracy
Project Start
2012-07-01
Project End
2016-02-29
Budget Start
2015-12-01
Budget End
2016-02-29
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California Davis
Department
Psychiatry
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Lorang, Emily; Sterling, Audra; Expressive Language Consortium (2017) The impact of autism spectrum disorder symptoms on gesture use in fragile X syndrome and Down syndrome. Autism Dev Lang Impair 2:
Visootsak, Jeannie; Huddleston, Lillie; Buterbaugh, Allison et al. (2016) Influence of CHDs on psycho-social and neurodevelopmental outcomes in children with Down syndrome. Cardiol Young 26:250-6
Edgin, Jamie O; Tooley, Ursula; Demara, Bianca et al. (2015) Sleep Disturbance and Expressive Language Development in Preschool-Age Children With Down Syndrome. Child Dev 86:1984-98
Edgin, Jamie O; Spanò, Goffredina; Kawa, Kevin et al. (2014) Remembering things without context: development matters. Child Dev 85:1491-502
Fernandez, Fabian; Edgin, Jamie O (2013) Poor Sleep as a Precursor to Cognitive Decline in Down Syndrome : A Hypothesis. J Alzheimers Dis Parkinsonism 3:124